Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:05am, Wednesday, 23'rd Oct 2024
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 12 Buys
08:10am, Wednesday, 23'rd Oct 2024
September's investment activity was minimal, with $1,000 invested mainly in Business Development Companies, while I traveled through Hungary, Albania, and Oman. Traveling highlighted the benefits of l
Beat the Nasdaq With This Cash-Gushing Dividend Stock
06:50am, Wednesday, 23'rd Oct 2024
The company is performing well despite recently losing its biggest growth driver.
AbbVie: Strong Dividends But Humira Disappoints
07:48am, Tuesday, 22'nd Oct 2024
Healthcare stocks are both defensive and present a mean reversion opportunity, making them attractive for risk-averse investors. Revenue exposure analysis shows consistent growth trends over 10 years,
The Only Product of Its Kind Approved for Use in Four Aesthetic Indications: Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines, Frown Lines, Crow's Feet Lines, and Now Platy
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
10:05am, Friday, 18'th Oct 2024
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
3 Growth Stocks That Could Be Bargain Buys Right Now
05:20am, Friday, 18'th Oct 2024
These stocks trade at less than 20 times their estimated future profits.
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
06:51pm, Thursday, 17'th Oct 2024
AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly
02:15pm, Thursday, 17'th Oct 2024
The Investment Committee debate the latest Calls Of The Day.
AbbVie wins FDA nod for infusion treatment for advanced Parkinson's disease
08:33am, Thursday, 17'th Oct 2024
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson's disease.
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
08:00am, Thursday, 17'th Oct 2024
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV re
A total of 12 abstracts, including four Best of Cosmetic Abstracts, demonstrate Allergan Aesthetics' commitment to patient outcomes and detailed insights and understanding of key concerns across diffe
Dividend Aristocrat AbbVie Just Paid Investors; Here's How Much They Received
09:59am, Tuesday, 15'th Oct 2024
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.
2 Magnificent Dividend Stocks to Buy and Hold Forever
09:45am, Monday, 14'th Oct 2024
These companies have compelling track records.
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
07:01am, Monday, 14'th Oct 2024
The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the heal
